Palvella Therapeutics, Inc.
PVLA· Nasdaq
PVLAPalvella Therapeutics, Inc.
Filed Mar 31, 2026 · 10-K · 90 days after period end · 0001193125-26-133372
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | $1.30M | $5.85M |
| Net Income | -$12.71M | -$3.95M | $38.65M | -$8.10M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
ended Dec 31, 2025 · filed Mar 31, 2026 · 90 d after period end
